[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632269":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":23,"centralContacts":32,"locations":38,"responsibleParty":57,"collaborators":23,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":23,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":23,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":23,"overallStatus":40,"whyStopped":23,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group L","EXPERIMENTAL","Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.",[13],"Drug: Ondansetron lozenge",{"label":15,"type":10,"description":16,"interventionNames":17},"Group O","Patients will receive 8 mg of ondansetron IV just before the surgery.",[18],"Drug: Ondansetron intravenous",{"label":20,"type":21,"description":22,"interventionNames":23},"Group C","NO_INTERVENTION","Patients will not receive ondansetron as a control group.",null,[25,29],{"type":26,"name":27,"description":11,"armGroupLabels":28,"otherNames":23},"DRUG","Ondansetron lozenge",[9],{"type":26,"name":30,"description":16,"armGroupLabels":31,"otherNames":23},"Ondansetron intravenous",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":23,"email":37},"Mohammed S Elsharkawy, MD","CONTACT","00201148207870","mselsharkawy@med.tanta.edu.eg",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Tanta","El-Gharbia","31527","Egypt","EG",{"type":47,"coordinates":48},"Point",[49,50],31.00192,30.78847,{"lat":50,"lon":49},[53,54],{"name":34,"role":35,"phone":36,"phoneExt":23,"email":37},{"name":55,"role":56,"phone":23,"phoneExt":23,"email":23},"Salma E Kandil, MD","PRINCIPAL_INVESTIGATOR",{"type":56,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Mohammed Said ElSharkawy","Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt","100632269","ondansetron-lozenge-versus-intravenous-for-prevention-of-shivering-in-cesarean-section-100632269",false,"NCT07511491","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 18 to 40 years.\n* American Society of Anesthesiology (ASA) physical status II.\n* Parturient women undergoing cesarean section under spinal anesthesia.\n\nExclusion Criteria:\n\n* Parturient women with any contraindication or hypersensitivity to the study drugs.\n* Any history of cardiovascular diseases, psychosis, hypertension, fetal distress, cord prolapse initial.\n* Preoperative shivering.\n* Preoperative fever (\\>38°C).\n* Body mass index \\> 40 kg\u002Fm2.\n* Medical history of alcohol or drug abuse.\n* Hypo- or hyperthyroidism.\n* Parkinson's disease or any extrapyramidal disease.\n* Intraoperative blood transfusion.","FEMALE","18 Years","40 Years",{"count":71,"type":72},90,"ESTIMATED","INTERVENTIONAL",[75],"NA","This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in cesarean section (CS).",[78,79,80,81,82,83],"Ondansetron","Lozenge","Intravenous","Prevention","Shivering","Cesarean Section","2026-06-22",{"date":86,"type":87},"2026-06-23","ACTUAL",{"date":89,"type":87},"2026-04-11",{"date":91,"type":72},"2026-08-30",{"name":5,"class":6},1]